Literature DB >> 22236921

False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications.

A Van Rie1, K Mellet, M-A John, L Scott, L Page-Shipp, H Dansey, T Victor, R Warren.   

Abstract

The World Health Organization had endorsed Xpert® MTB/RIF (Xpert) as the initial diagnostic for multidrug-resistant tuberculosis (TB) or TB suspects co-infected with the human immunodeficiency virus. We investigated an unexpected case of rifampicin (RMP) resistance on Xpert using repeat Xpert, smear microscopy, MTBDRplus assay, culture, drug susceptibility testing, spoligotyping and rpoB gene sequencing. A false-positive result was most likely, given the wild type rpoB gene sequence and exclusion of both mixed infection and mixture of drug-susceptible and drug-resistant populations. When decentralising Xpert, test performance characteristics need to be understood by health care workers and methods of confirmation of RMP resistance need to be accessible.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236921      PMCID: PMC3680645          DOI: 10.5588/ijtld.11.0395

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  8 in total

1.  Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.

Authors:  Grant Theron; Jonny Peter; Richard van Zyl-Smit; Hridesh Mishra; Elizabeth Streicher; Samuel Murray; Rodney Dawson; Andrew Whitelaw; Michael Hoelscher; Surendra Sharma; Madhukar Pai; Robin Warren; Keertan Dheda
Journal:  Am J Respir Crit Care Med       Date:  2011-04-14       Impact factor: 21.405

2.  Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens.

Authors:  Elizabeth M Marlowe; Susan M Novak-Weekley; Joven Cumpio; Susan E Sharp; Michelle A Momeny; Anna Babst; Jonathan S Carlson; Masae Kawamura; Mark Pandori
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

3.  Resistance to pyrazinamide and ethambutol compromises MDR/XDR-TB treatment.

Authors:  K G P Hoek; H S Schaaf; N C Gey van Pittius; P D van Helden; R M Warren
Journal:  S Afr Med J       Date:  2009-11

4.  Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology.

Authors:  J Kamerbeek; L Schouls; A Kolk; M van Agterveld; D van Soolingen; S Kuijper; A Bunschoten; H Molhuizen; R Shaw; M Goyal; J van Embden
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

5.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

Review 6.  Drug resistance in Mycobacterium tuberculosis.

Authors:  Rabia Johnson; Elizabeth M Streicher; Gail E Louw; Robin M Warren; Paul D van Helden; Thomas C Victor
Journal:  Curr Issues Mol Biol       Date:  2006-07       Impact factor: 2.081

7.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.

Authors:  Catharina C Boehme; Mark P Nicol; Pamela Nabeta; Joy S Michael; Eduardo Gotuzzo; Rasim Tahirli; Ma Tarcela Gler; Robert Blakemore; William Worodria; Christen Gray; Laurence Huang; Tatiana Caceres; Rafail Mehdiyev; Lawrence Raymond; Andrew Whitelaw; Kalaiselvan Sagadevan; Heather Alexander; Heidi Albert; Frank Cobelens; Helen Cox; David Alland; Mark D Perkins
Journal:  Lancet       Date:  2011-04-18       Impact factor: 79.321

8.  Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study.

Authors:  Stephen D Lawn; Sophie V Brooks; Katharina Kranzer; Mark P Nicol; Andrew Whitelaw; Monica Vogt; Linda-Gail Bekker; Robin Wood
Journal:  PLoS Med       Date:  2011-07-26       Impact factor: 11.069

  8 in total
  35 in total

1.  Rifampin drug resistance tests for tuberculosis: challenging the gold standard.

Authors:  Armand Van Deun; Kya J M Aung; Valentin Bola; Rossin Lebeke; Mohamed Anwar Hossain; Willem Bram de Rijk; Leen Rigouts; Aysel Gumusboga; Gabriela Torrea; Bouke C de Jong
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

2.  Evaluation of OMNIgene Sputum and Ethanol Reagent for Preservation of Sputum Prior to Xpert and Culture Testing in Uganda.

Authors:  Elisa Ardizzoni; Patrick Orikiriza; Charles Ssuuna; Dan Nyehangane; Mourad Gumsboga; Ivan Mugisha Taremwa; Esther Turyashemererwa; Juliet Mwanga-Amumpaire; Céline Langendorf; Maryline Bonnet
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

3.  False-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load.

Authors:  Oksana Ocheretina; Erin Byrt; Marie-Marcelle Mabou; Gertrude Royal-Mardi; Yves-Mary Merveille; Vanessa Rouzier; Daniel W Fitzgerald; Jean W Pape
Journal:  Diagn Microbiol Infect Dis       Date:  2016-01-15       Impact factor: 2.803

4.  Xpert MTB/RIF false detection of rifampin-resistant tuberculosis from prior infection.

Authors:  J Daniel Kelly; Shou-Yean Grace Lin; Pennan M Barry; Chris Keh; Julie Higashi; John Z Metcalfe
Journal:  Am J Respir Crit Care Med       Date:  2014-12-01       Impact factor: 21.405

Review 5.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

6.  Retrospective Analysis of False-Positive and Disputed Rifampin Resistance Xpert MTB/RIF Assay Results in Clinical Samples from a Referral Hospital in Hunan, China.

Authors:  Peilei Hu; Hongtai Zhang; Joy Fleming; Guofeng Zhu; Shuai Zhang; Yaguo Wang; Fengping Liu; Songlin Yi; Zhongnan Chen; Zhenhua Chen; Binbin Liu; Daofang Gong; Li Wan; Xingyun Wang; Yunhong Tan; Liqiong Bai; Lijun Bi
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

7.  Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens.

Authors:  S-Y Grace Lin; Timothy C Rodwell; Thomas C Victor; Errin C Rider; Lucy Pham; Antonino Catanzaro; Edward P Desmond
Journal:  J Clin Microbiol       Date:  2013-11-27       Impact factor: 5.948

8.  MTBDRplus for the rapid diagnosis of ocular tuberculosis and screening of drug resistance.

Authors:  K Sharma; A Gupta; M Sharma; A Sharma; R Singh; K Aggarwal; R Bansal; A Thakur; S Prakash; V Gupta
Journal:  Eye (Lond)       Date:  2017-10-20       Impact factor: 3.775

9.  Unsuccessful Xpert® MTB/RIF results: the Nigerian experience.

Authors:  M Gidado; N Nwokoye; P Nwadike; P Ajiboye; R Eneogu; S Useni; J Onazi; A Lawanson; E Elom; A Tubi; J Kuye
Journal:  Public Health Action       Date:  2018-03-21

Review 10.  Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

Authors:  Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.